Arrowstreet Capital, Limited Partnership Ascendis Pharma A/S Transaction History

Arrowstreet Capital, Limited Partnership

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$99.42 - $131.97 $2.9 Million - $3.86 Million	29,218 New	29,218 $3.57 Million
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $865,516 - $1.3 Million	11,085 Added 548.76%	13,105 $1.22 Million
Q1 2022 May 13, 2022	BUY	$102.18 - $135.75 $206,403 - $274,215	2,020 New	2,020 $237,000
Q2 2020 Aug 12, 2020	SELL	$110.87 - $156.01 $388,045 - $546,035	-3,500 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$97.01 - $145.11 $339,535 - $507,885	3,500 New	3,500 $394,000
Q4 2019 Feb 13, 2020	SELL	$91.45 - $139.12 $1.25 Million - $1.91 Million	-13,700 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $1.31 Million - $1.63 Million	13,700 New	13,700 $1.32 Million
Q1 2019 May 15, 2019	SELL	$62.15 - $129.99 $1.6 Million - $3.35 Million	-25,799 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$55.16 - $69.67 $302,497 - $382,070	5,484 Added 26.99%	25,799 $1.62 Million
Q3 2018 Nov 14, 2018	SELL	$63.77 - $76.28 $550,781 - $658,830	-8,637 Reduced 29.83%	20,315 $1.44 Million
Q2 2018 Aug 14, 2018	BUY	$58.55 - $73.92 $1.7 Million - $2.14 Million	28,952 New	28,952 $1.93 Million

244

58.8M

250K

377K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $7.61B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.